Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an update.
Radiopharm Theranostics Limited has announced a proposed issue of securities, including options expiring in 2027 and ordinary fully paid shares, scheduled for issuance on December 10, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market position by enhancing its financial resources for ongoing and future projects, thereby influencing stakeholders’ interests and the company’s operational capabilities.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the medical technology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is engaged in creating innovative solutions for cancer treatment and diagnosis, aiming to enhance patient outcomes through advanced theranostic technologies.
Average Trading Volume: 4,552,171
Technical Sentiment Signal: Buy
Current Market Cap: A$87.5M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.